NDA 213330 · Hikma
Labetalol Hydrochloride
Labetalol Hydrochloride · Intravenous
Last checked: Nov 19, 2026Latest source record: Aug 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Nov 9, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
79
12 Phase 3, 13 recruiting
FAERS reports
13,484
10,245 serious, 1,375 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 19, 2025.
Labetalol HCl Injection is indicated in severe hypertension, to lower blood pressure. Labetalol Hydrochloride (HCl) is a beta-adrenergic blocker. Labetalol HCl injection is indicated in severe hypertension, to lower blood pressure. ( 1 )
Mechanism: Labetalol has both competitive alpha1-adrenergic blocking and competitive beta-adrenergic blocking activity. In man, the ratio of alpha- to beta-blockade has been estimated to be approximately 1:7 following intravenous administration. Beta 2 -agonist activity has been demonstrated in animals with minimal beta 1 -agonist activity detected.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
6 products under this application
- LABETALOL HYDROCHLORIDE · LABETALOL HYDROCHLORIDE 10MG/2ML (5MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
- LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE · LABETALOL HYDROCHLORIDE 200MG/200ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- LABETALOL HYDROCHLORIDE IN DEXTROSE · LABETALOL HYDROCHLORIDE 200MG/200ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- LABETALOL HYDROCHLORIDE · LABETALOL HYDROCHLORIDE 20MG/4ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE · LABETALOL HYDROCHLORIDE 300MG/300ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE · LABETALOL HYDROCHLORIDE 100MG/100ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Labetalol" as an intervention, any sponsor and status, largest first.
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01422616 · 4,587 participants · Start Mar 2012 · Primary completion Aug 2018
Drug: Low-dose rtPA; Standard-dose rtPA · For: Ischemic Stroke; High Blood Pressure
Sites: Sydney, Australia
- Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST TrialPivotal-lookingNot yet recruiting
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT07746271 · 4,120 participants (planned) · Start Sep 30, 2026 · Primary completion Dec 31, 2029
Drug: Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg · For: Hypertension in Pregnancy; Obstetrical Complications
Sites: Birmingham, Alabama; San Francisco, California; Chicago, Illinois · 14 sites in all
- Chronic Hypertension and Pregnancy (CHAP) ProjectPivotal-lookingCompleted
University of Alabama at BirminghamAcademic, hospital or other
NCT02299414 · 2,408 participants · Start Jun 2015 · Primary completion Apr 1, 2022
Drug: Anti-hypertensive therapy · For: Hypertension
Sites: Birmingham, Alabama; Mobile, Alabama; Little Rock, Arkansas · 72 sites in all
- Intensive Arterial Pressure Control in Acute Coronary SyndromePivotal-lookingCompleted
University of MonastirAcademic, hospital or other
NCT02135315 · 1,500 participants · Start Mar 2014 · Primary completion Dec 31, 2020
Drug: Isosorbide Dinitrate · For: Acute Coronary Syndrome
Sites: Monastir, Tunisia
- Antihypertensive Treatment of Acute Cerebral Hemorrhage-IIPivotal-lookingTerminated
University of MinnesotaAcademic, hospital or other
NCT01176565 · 1,000 participants · Start May 15, 2011 · Primary completion Dec 21, 2015
Drug: Intravenous nicardipine hydrochloride · For: Intracerebral Hemorrhage
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 171 sites in all
- Oral Antihypertensive Regimens for Management of Hypertension in PregnancyPivotal-lookingCompleted
Gynuity Health ProjectsAcademic, hospital or other
NCT01912677 · 894 participants · Start Apr 2015 · Primary completion Sep 2017
Drug: Nifedipine; Labetalol and 1 more · For: Hypertension in Pregnancy; Preeclampsia
Sites: Nagpur, India · 2 sites in all
- Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled TrialPivotal-lookingRecruiting
Nebraska Methodist Health SystemAcademic, hospital or other
NCT05309460 · 600 participants (planned) · Start Jun 20, 2022 · Primary completion May 1, 2024
Drug: Labetalol Oral Tablet; NIFEdipine ER · For: Postpartum Preeclampsia; Hypertension in Pregnancy
Sites: Omaha, Nebraska
- Safest Choice of Antihypertensive Regimen for Postpartum HypertensionPivotal-lookingRecruiting
Loma Linda UniversityAcademic, hospital or other
NCT05551104 · 500 participants (planned) · Start May 8, 2023 · Primary completion Dec 2027
Drug: Oral Nifedipine; Oral Labetalol · For: Postpartum Complication; Maternal Hypertension; High Blood Pressure
Sites: Loma Linda, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,060
- maternal exposure during pregnancy1,001
- foetal exposure during pregnancy976
- hypertension767
- premature baby752
- off label use726
- exposure during pregnancy672
- chronic kidney disease646
- acute kidney injury645
- fatigue616
- renal failure581
- nausea555
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 59 |
| 2005 | 137 |
| 2006 | 66 |
| 2007 | 42 |
| 2008 | 44 |
| 2009 | 54 |
| 2010 | 74 |
| 2011 | 197 |
| 2012 | 213 |
| 2013 | 438 |
| 2014 | 709 |
| 2015 | 751 |
| 2016 | 757 |
| 2017 | 944 |
| 2018 | 1,068 |
| 2019 | 1,223 |
| 2020 | 1,144 |
| 2021 | 1,100 |
| 2022 | 1,017 |
| 2023 | 908 |
| 2024 | 956 |
| 2025 | 857 |
| 2026 | 726 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral antihypertensive treatment during pregnancy: a systematic review and network meta-analysis.
Hup RJ, Damen JAA, Terstappen J, et al. · Am J Obstet Gynecol 2025 · Network Meta-Analysis, Systematic Review
- First-line antihypertensive treatment for severe hypertension in pregnancy: A systematic review and network meta-analysis.
Alavifard S, Chase R, Janoudi G, et al. · Pregnancy Hypertens 2019 · Systematic Review, Network Meta-Analysis
- β-Blockers, Cocaine, and the Unopposed α-Stimulation Phenomenon.
Richards JR, Hollander JE, Ramoska EA, et al. · J Cardiovasc Pharmacol Ther 2017 · Systematic Review
- Anti-hypertensive therapy for preeclampsia: a network meta-analysis and systematic review.
Wang T, Jiang R, Yao Y, et al. · Hypertens Pregnancy 2024 · Systematic Review, Network Meta-Analysis
- Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial.
S D, Novri DA, Hamidy Y, et al. · F1000Res 2022 · Randomized Controlled Trial
- Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.
van de Vusse D, Mian P, Schoenmakers S, et al. · Eur J Clin Pharmacol 2022 · Systematic Review
Sponsor: Hikma · Also marketed as Labetalol Hydrochloride In Sodium Chloride, Labetalol Hydrochloride In Dextrose
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.